Abstract
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of Antimicrobial Chemotherapy |
| Vol/bind | 63 |
| Udgave nummer | 2 |
| Sider (fra-til) | 400-404 |
| Antal sider | 4 |
| ISSN | 0305-7453 |
| DOI | |
| Status | Udgivet - 2009 |
Bibliografisk note
Keywords: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Bacteria; Bacterial Infections; Cohort Studies; Community-Acquired Infections; Decision Support Systems, Clinical; Denmark; Drug Resistance, Bacterial; Female; Health Services Research; Hospitals, University; Humans; Male; Middle Aged; Retrospective StudiesAdgang til dokumentet
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Performance of the TREAT decision support system in an environment with a low prevalence of resistant pathogens. / Kofoed, Kristian; Zalounina, Alina; Andersen, Ove; Lisby, Gorm; Paul, Mical; Leibovici, Leonard; Andreassen, Steen; Kofoed, Kristian; Zalounina, Alina; Andersen, Ove; Lisby, Gorm; Paul, Mical; Leibovici, Leonard; Andreassen, Steen.
I: Journal of Antimicrobial Chemotherapy, Bind 63, Nr. 2, 2009, s. 400-404.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Performance of the TREAT decision support system in an environment with a low prevalence of resistant pathogens
AU - Kofoed, Kristian
AU - Zalounina, Alina
AU - Andersen, Ove
AU - Lisby, Gorm
AU - Paul, Mical
AU - Leibovici, Leonard
AU - Andreassen, Steen
AU - Kofoed, Kristian
AU - Zalounina, Alina
AU - Andersen, Ove
AU - Lisby, Gorm
AU - Paul, Mical
AU - Leibovici, Leonard
AU - Andreassen, Steen
N1 - Keywords: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Bacteria; Bacterial Infections; Cohort Studies; Community-Acquired Infections; Decision Support Systems, Clinical; Denmark; Drug Resistance, Bacterial; Female; Health Services Research; Hospitals, University; Humans; Male; Middle Aged; Retrospective Studies
PY - 2009
Y1 - 2009
N2 - OBJECTIVES: To evaluate a decision support system (TREAT) for guidance of empirical antimicrobial therapy in an environment with a low prevalence of resistant pathogens. METHODS: A retrospective trial of TREAT has been performed at Copenhagen University, Hvidovre Hospital. The cohort of patients included adults with systemic inflammation and suspicion of community-acquired bacterial infection. The empirical antimicrobial treatment recommended by TREAT was compared with the empirical antimicrobial treatment prescribed by the first attending clinical physician. RESULTS: Out of 171 patients recruited, 161 (65 with microbiologically documented infections) fulfilled the inclusion criteria of TREAT. Coverage achieved by TREAT was significantly higher than that by clinical practice (86% versus 66%, P = 0.007). There was no significant difference in the cost of future resistance between treatments chosen by TREAT and those by physicians. The direct expenses for antimicrobials were higher in TREAT when including patients without antimicrobial treatment, while there was no significant difference otherwise. The cost of side effects was significantly lower using TREAT. CONCLUSIONS: The results of the study suggest that TREAT can improve the appropriateness of antimicrobial therapy and reduce the cost of side effects in regions with a low prevalence of resistant pathogens, however, at the expense of increased use of antibiotics.
AB - OBJECTIVES: To evaluate a decision support system (TREAT) for guidance of empirical antimicrobial therapy in an environment with a low prevalence of resistant pathogens. METHODS: A retrospective trial of TREAT has been performed at Copenhagen University, Hvidovre Hospital. The cohort of patients included adults with systemic inflammation and suspicion of community-acquired bacterial infection. The empirical antimicrobial treatment recommended by TREAT was compared with the empirical antimicrobial treatment prescribed by the first attending clinical physician. RESULTS: Out of 171 patients recruited, 161 (65 with microbiologically documented infections) fulfilled the inclusion criteria of TREAT. Coverage achieved by TREAT was significantly higher than that by clinical practice (86% versus 66%, P = 0.007). There was no significant difference in the cost of future resistance between treatments chosen by TREAT and those by physicians. The direct expenses for antimicrobials were higher in TREAT when including patients without antimicrobial treatment, while there was no significant difference otherwise. The cost of side effects was significantly lower using TREAT. CONCLUSIONS: The results of the study suggest that TREAT can improve the appropriateness of antimicrobial therapy and reduce the cost of side effects in regions with a low prevalence of resistant pathogens, however, at the expense of increased use of antibiotics.
U2 - 10.1093/jac/dkn504
DO - 10.1093/jac/dkn504
M3 - Journal article
C2 - 19091808
VL - 63
SP - 400
EP - 404
JO - Journal of Antimicrobial Chemotherapy
JF - Journal of Antimicrobial Chemotherapy
SN - 0305-7453
IS - 2
ER -